Drug Trial Radar · NCT02254967
A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population
Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
364
Actual
Start
Nov 6, 2014
Primary completion
Mar 27, 2016
Study completion May 5, 2016
Sponsor
- Lead sponsor
- Astellas Pharma Europe Ltd.Astellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the study is to evaluate whether the extended duration fidaxomicin therapy is superior to the standard vancomycin therapy in sustained clinical cure of CDI at 30 days after end of treatment (Day 40 or Day 55).
Conditions
- Clostridium Difficile
Interventions
FidaxomicinDrug
oral tablets administered in an extended pulsed regimen
VancomycinDrug
oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with a Sustained Clinical Cure of CDI at 30 Days after End of TreatmentTime frame: Day 40 (for vancomycin) and day 55 (for fidaxomicin extended pulsed regimen [EPFX])
Locations
109 sites in 22 countries. Site status is shown where the registry gives one.
Site AT43002
Graz, Austria
Site AT43003
Linz, Austria
Site AT43001
Salzburg, Austria
Site BE32007
Aalst, Belgium
Site BE32006
Bruges, Belgium
Site BE32001
Brussels, Belgium
Site BE32005
Brussels, Belgium
Site BE32008
Liège, Belgium
Site HR38506
Osijek, Croatia
Site HR38503
Rijeka, Croatia
Site HR38505
Zadar, Croatia
Site HR38501
Zagreb, Croatia
Site CZ42002
Brno-Bohunice, Czechia
Site CZ42005
Kyjov, Czechia
Site CZ42004
Opava, Czechia
Site CZ42003
Prague, Czechia
Site CZ42001
Praha 8 - Libeň, Czechia
Site DK45001
Herlev, Denmark
Site DK45005
Hillerød, Denmark
Site DK45004
Nykøbing Falster, Denmark
Site FI35801
Helsinki, Finland
Site FI35802
Turku, Finland
Site FR33003
Bordeaux, France
Site FR33008
Clermont-Ferrand, France
Site FR33006
Lille, France
Site FR33005
Nantes, France
Site FR33004
Nîmes, France
Site FR33001
Paris, France
Site FR33007
Paris, France
Site FR33002
Rennes, France
Site FR33009
Saint-Priest-en-Jarez, France
Site DE49001
Cologne, Germany
Site DE49011
Cologne, Germany
Site DE49012
Hamburg, Germany
Site DE49006
Leipzig, Germany
Site DE49016
Lübeck, Germany
Site DE49008
Marburg, Germany
Site GR30005
Athens, Greece
Site GR30008
Athens, Greece
Site GR30001
Athens, Greece
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.